விட்ஸ் வணிகரீதியானது நிறுவன News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from விட்ஸ் வணிகரீதியானது நிறுவன. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In விட்ஸ் வணிகரீதியானது நிறுவன Today - Breaking & Trending Today

2021-03 - Wits and Biovac partner to develop skills to produce viral vectored vaccines in South Africa

8 March 2021 - Wits University
The Antiviral Gene Therapy Research Unit via Wits Enterprise has partnered with Biovac to develop the skills capacity to produce viral vectored vaccines in SA.
Demonstrating that South Africa has the capability and the skills resources to tackle serious health problems, Wits University’s Antiviral Gene Therapy Research Unit (AGTRU), with Wits Commercial Enterprise acting on its behalf, partnered with Cape Town based bio-pharmaceutical company, Biovac, in a partnership announced on 2 March 2021.
Wits Enterprise is a private company wholly owned by Wits University and mandated to promote and commercialise Wits’ intellectual capital, research and innovations, so as to broaden and deepen the University s societal impact. ....

Cape Town , Western Cape , South Africa , South African , Patrick Arbuthnot , Morena Makhoana , Wits University Antiviral Gene Therapy Research Unit , Wits University , Antiviral Gene Therapy Research Unit , Wits South African Medical Research Council , Wits Enterprise , Wits Commercial Enterprise , Personal Professor , South African Medical Research Council , கேப் நகரம் , மேற்கு கேப் , பேட்ரிக் அர்புதனோட , விட்ஸ் பல்கலைக்கழகம் , விட்ஸ் நிறுவன , விட்ஸ் வணிகரீதியானது நிறுவன , தனிப்பட்ட ப்ரொஃபெஸர் ,

Wits, Biovac to develop skills capacity to produce viral vectored vaccines

(Getty Images)
The University of the Witwatersrand s Antiviral Gene Therapy Research Unit will assist with building specialist skills capacity within Biovac to generate engineered viruses that may be used as Covid-19 and other vaccines.
According to Biovac, South Africa desperately needs to build capability to manufacture viral vaccines from scratch rather than importing the active pharmaceutical ingredients.
Viral vector-based vaccines are different from most conventional vaccines as they use the body s cells to produce antigens.
The University of the Witwatersrand s Antiviral Gene Therapy Research Unit has partnered with partly state-owned bio-pharmaceutical company Biovac to develop skills capacity to produce viral vectored vaccines. ....

South Africa , South African , Patrick Arbuthnot , Morena Makhoana , Antiviral Gene Therapy Research Unit , Professor Patrick , Wits Commercial Enterprise , பேட்ரிக் அர்புதனோட , ப்ரொஃபெஸர் பேட்ரிக் , விட்ஸ் வணிகரீதியானது நிறுவன ,